Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Novartis Ag ADR (NVS)
Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 209,649,664
  • Shares Outstanding, K 2,119,600
  • Annual Sales, $ 51,828 M
  • Annual Income, $ 6,955 M
  • 60-Month Beta 0.54
  • Price/Sales 4.07
  • Price/Cash Flow 15.28
  • Price/Book 3.91
Trade NVS with:

Options Overview Details

View History
  • Implied Volatility 17.42% ( -3.87%)
  • Historical Volatility 17.03%
  • IV Percentile 12%
  • IV Rank 13.73%
  • IV High 27.17% on 03/02/23
  • IV Low 15.87% on 03/24/23
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,122
  • Volume Avg (30-Day) 2,343
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 93,412
  • Open Int (30-Day) 78,218

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 1.66
  • Number of Estimates 4
  • High Estimate 1.69
  • Low Estimate 1.64
  • Prior Year 1.56
  • Growth Rate Est. (year over year) +6.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.34 +3.74%
on 05/31/23
105.35 -6.11%
on 05/08/23
-4.63 (-4.47%)
since 05/02/23
3-Month
79.98 +23.67%
on 03/09/23
105.56 -6.30%
on 04/25/23
+13.79 (+16.20%)
since 03/02/23
52-Week
74.09 +33.50%
on 09/26/22
105.56 -6.30%
on 04/25/23
+9.12 (+10.16%)
since 06/02/22

Most Recent Stories

More News
3 Value Stocks to Add to Your Portfolio

The stock market will likely remain under pressure with rising concerns about an economic slump and high-interest rates. Therefore, investors could look to add fundamentally strong stocks Novo Nordisk...

NTCT : 31.31 (+2.93%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
Is SNDL Inc. (SNDL) Overbought?

Canadian cannabis company SNDL Inc. (SNDL) enjoys major investor attention and belongs to the Robinhood top 100 stocks list. However, should investors consider buying this stock now? Read more… ...

ABBV : 136.87 (+2.57%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
SNDL : 1.4800 (+2.07%)
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin

MRNA : 130.51 (+1.55%)
PFE : 38.36 (+0.89%)
IOVA : 8.80 (+0.80%)
NVS : 98.91 (+1.85%)
BMY : 65.66 (+1.52%)
MRK : 112.52 (+1.43%)
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years

These two pharmaceutical companies have created value for shareholders.

AZN : 72.59 (-0.34%)
MRK : 112.52 (+1.43%)
NVS : 98.91 (+1.85%)
JNJ : 156.97 (+1.57%)
LLY : 442.33 (+1.34%)
Should You Add Shares of Tilray Brands (TLRY) to Your Portfolio?

Canadian cannabis leader Tilray Brands (TLRY) is bolstering its portfolio through expansions and partnerships. However, the company’s recent $150 million offering of senior notes put pressure on its...

ABBV : 136.87 (+2.57%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
TLRY : 1.7200 (+1.18%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END

ONCY : 1.7200 (+3.61%)
ONC.TO : 2.28 (+1.79%)
PFE : 38.36 (+0.89%)
OCEA : 5.50 (-3.85%)
NVS : 98.91 (+1.85%)
RLAY : 11.47 (+3.71%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

/PRNewswire/ -- Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from...

ONC.TO : 2.28 (+1.79%)
ONCY : 1.7200 (+3.61%)
PFE : 38.36 (+0.89%)
OCEA : 5.50 (-3.85%)
NVS : 98.91 (+1.85%)
RLAY : 11.47 (+3.71%)
Buy, Sell, or Hold: Pfizer Inc. (PFE)

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out… ...

IRWD : 11.03 (+1.38%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
Dr. Reddy's Laboratories (RDY) Is the Pharmaceutical Stock to Buy

Dr. Reddy's Laboratories (RDY) delivered exceptional performance, as its fourth-quarter profits grew by an astonishing eleven-fold. By deftly expanding its product line-up and fortifying its market presence,...

ABBV : 136.87 (+2.57%)
BMY : 65.66 (+1.52%)
NVS : 98.91 (+1.85%)
RDY : 56.72 (+1.61%)
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market

Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.

NVS : 98.91 (+1.85%)
LLY : 442.33 (+1.34%)
MRK : 112.52 (+1.43%)
NVO : 157.14 (-0.53%)
SWAV : 289.15 (+2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 100.30
2nd Resistance Point 99.62
1st Resistance Point 99.26
Last Price 98.91
1st Support Level 98.22
2nd Support Level 97.54
3rd Support Level 97.18

See More

52-Week High 105.56
Last Price 98.91
Fibonacci 61.8% 93.54
Fibonacci 50% 89.82
Fibonacci 38.2% 86.11
52-Week Low 74.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar